AVANTHI INC
GenericsAVANTHI INC is a generic drug manufacturer focused on Metabolic.
AVANTHI INC's Key Drugs
AVANTHI INC's core commercial portfolio centers on LOMAIRA, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
AVANTHI INC's Recent FDA Approvals
New NDA/BLA approvals for AVANTHI INC over the last two years — novel drugs only, excluding generics and label supplements.
AVANTHI INC's Therapeutic Areas
AVANTHI INC's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVANTHI INC's Top Competitors
AVANTHI INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVANTHI INC Pipeline Snapshot
Active clinical trials for AVANTHI INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LOMAIRA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (1)
Company Info
- First Approval
- 2009-03-06
- Latest
- 2026-06-18
- Applications
- 10